Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07796880 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Name: Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer — clinical trial record (NCT07796880)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Started2026-09-14

View on ClinicalTrials.gov ↗

Amendment history

2026-09-16

Recruitment opened

Trial started: 2026-09-14 (last estimated 2026-09-15)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

247 trials monitored

See 2 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant Culmerciclib combined with aromatase inhibitor versus aromatase-inhibitor monotherapy in patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative early-stage breast cancer.

Trial Details

NCT Number	NCT07796880
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
Enrollment	80 participants
Start Date	2026-09-14
Primary Completion	2028-09-15 (estimated)
Study Completion	2033-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-09-15